How Come The Aldeyra (ALDX) Stock Has Been Rising In Pre-Market Trades?

0
1154
GILD Stock
GILD Stock

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) rose 6.59% to trade at $12.78 per share at last check-in premarket trading. During Tuesday’s session, Aldeyra stock fell -4.00%, closing at $11.99. The daily volume of ALDX stock was 1.74 million shares, which was less than the 50-day average of 2.7 million shares. In the run-up to tomorrow’s quarterly results, ALDX stock has been going up.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What is ALDX aiming at?


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Aldeyra Therapeutics is a clinical-stage biotechnology company specializing in finding new ways to treat patients with immune-mediated diseases. RASP (reactive aldehyde species) are elevated in ocular and systemic inflammatory disease, and they are targets of ADX-629 and reproxalap, two of the ALDX’s lead investigational compounds. ALDX’s clinical pipeline also includes ADX-2191, an inhibitor of dihydrofolate reductase in Phase 3 trials for proliferative vitreoretinopathy.

Read More

On May 6, 2021 at 8:00 a.m. ET, Aldeyra will host a conference call to report financial results and discuss recent business highlights, announced ALDX in a press release today.

Also in last week, ALDX announced that its 0.25% recproxalap ophthalmic solution, an investigational new drug, has been found to be safe and effective for patients with allergic conjunctivitis in the Phase 3 INVIGORATE Clinical Trial.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What ALDX is planning?

All secondary endpoints and the primary endpoint of the ALDX’s clinical trial were statistically significant. As part of its plans for the second half of 2021, Aldeyra (ALDX) will meet with the FDA to discuss the INVIGORATE results, along with the submission of a New Drug Application (NDA).

LEAVE A REPLY

Please enter your comment!
Please enter your name here